Journal
JOURNAL OF REPRODUCTIVE IMMUNOLOGY
Volume 149, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.jri.2021.103454
Keywords
Cervical cancer; IDO; Chemokine ligands; Chemokine receptors; Kynurenine; Tryptophan; HPV
Categories
Funding
- Department of Science and Technology, Govt. of India [SR/S9/Z-08/2010]
- Lady Tata Memorial Trust
- DST INSPIRE fellowship
- CSIR-JRF fellowship
Ask authors/readers for more resources
In cervical cancer, overexpression of IDO1 and elevated K/T levels were found in early and locally advanced stages. High CCL19 marker expression was identified as a good prognostic indicator for disease-free and overall survival. High levels of IDO1 expression may further reduce survival outcomes in patients with low CCL19 expression.
The over expression of Indoleamine 2, 3-Dioxygenase (IDO1), an immune checkpoint inhibitor, is well known in cervical cancer. However, its association with chemokine signals promoting cellular infiltration in the cervical tumor microenvironment, is unknown. In the current study, we evaluated the expression and enzymatic activity of IDO1. We also profiled the expression of chemokine ligand-receptors- CCR4-CCL22, CXCR3-CXCL10, CXCR-4CXCL12, and CCR7-CCL19 using immunohistochemistry (IHC), and studied their association with IDO1, statistically. After getting an informed consent, punch biopsy samples were obtained from 105 patients diagnosed with cervical cancer. HPV typing by Sanger sequencing, realtime PCR for quantifying IDO1 mRNA expression, HPLC for determining the K/T ratio and IHC for all the above chemokine receptor-ligand pairs along with IDO1 were performed. We found a significant increase in the expression of IDO1 and K/T levels in early and locally advanced stages when compared to Stage IV disease. Among the chemokine ligand-receptor pairs profiled, we found that high CCL19 marker expression was a good prognostic indicator of patients' disease-free (p = 0.013) and overall survival (p = 0.043). Although we could not identify IDO1 as an independent prognostic factor, we found that high levels of IDO1 expression may further reduce survival outcomes in patients with low CCL19 expression. This could be vital for designing immuno therapeutic interventions targeting IDO1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available